Sinaf

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinaf

What is Sinaf? Definition, Composition, and General Purpose

Property Description
Active Ingredients Oxymetazoline, Phenylephrine
Form Nasal Spray or Solution
Pharmacological Class Sympathomimetic, alpha-Adrenergic Agonist
Common Use Temporary relief of nasal congestion
Origin Synthetic

What Type of Medicine is Sinaf and What is its Pharmacological Class?

Sinaf is a synthetic combination product classified fundamentally as a decongestant medicine, belonging to the sympathomimetic pharmacological class. This means it is a type of drug that mimics the actions of the body's natural adrenaline-like substances on the nervous system. The specific active agents categorize Sinaf as an alpha-adrenergic agonist, a designation that identifies its primary mechanism of stimulating specific receptors on smooth muscle tissue. This classification defines the product's function as a local vasoconstrictor used for the relief of nasal swelling, an action that provides rapid and targeted relief in the nasal passages.

Composition: Oxymetazoline, Phenylephrine, and the Combination Product Identity

Sinaf contains two distinct active ingredients: Oxymetazoline Hydrochloride and Phenylephrine Hydrochloride. It is characterized as a combination product because it utilizes two separate active agents to exert its primary effect, distinguishing it from monotherapy decongestants. The medication is prepared as a liquid aqueous solution intended for topical nasal administration, typically dispensed as a nasal spray or nasal solution, which ensures localized delivery to the nasal passages. As a topical vasoconstrictor, Oxymetazoline induces relief from nasal obstruction.

General Purpose and Mechanism of Action (High-Level)

The general therapeutic purpose of Sinaf is to provide temporary and localized relief from nasal stuffiness and congestion, such as relief experienced during cold or flu symptoms. The core principle by which the medication operates is vasoconstriction, or the physical tightening of blood vessels. By acting on the alpha-adrenergic receptors in the nasal lining, the active ingredients cause the small blood vessels to constrict, which in turn reduces the swelling and congestion of the engorged nasal membranes. Decongestants function by making it easier to breathe through the nose. The primary goal of the medication is to facilitate air passage by reducing swelling.

Regulatory References

  1. NIH MedlinePlus (Oxymetazoline)
  2. NIH MedlinePlus (Phenylephrine Nasal Spray)

What side effects are possible with Sinaf?

Possible side effects and safety information for Sinaf

The official safety profile for any medicine, including Sinaf, is established and regulated by government health authorities, which categorize all known effects and restrictions.

Adverse Reaction Scope

Adverse reactions are formally listed by the body system affected (System Organ Class or SOC) and classified according to their documented frequency to convey the statistical probability of occurrence. These frequency categories range from Very Common (1/10) to Rare (< 1/1,000).

  • Key Adverse Reaction Categories: These typically involve reactions affecting the nervous system, the gastrointestinal tract, and general disorders.
  • Serious Adverse Reactions (SARs): The regulatory documentation designates specific, clinically significant events (SARs) that are critical to patient safety. These include severe hypersensitivity reactions and other events that could necessitate urgent medical intervention.
  • Population-Specific Safety Considerations: Restrictions are detailed for use in certain patient groups where risk may be elevated, such as the elderly or individuals with pre-existing hepatic or renal impairment.

Safety Restrictions and Limitations

Formal Contraindications define the circumstances and patient populations for whom the medicine is strictly prohibited, as the risks are officially determined to be unacceptable. The regulatory label may also contain mandatory Safety Monitoring Notes, outlining specific laboratory tests or clinical observations required to be followed during the course of treatment, particularly regarding organ function or potential drug interactions.

Structure of the Official Safety Profile

This structure systematically organizes the medicine’s risks, distinguishing between high-frequency, non-serious events and low-frequency, high-severity events (SARs). The inclusion of formal Contraindications and specific Restrictions establishes the essential safety boundaries for the medicine’s use, based solely on documented risk data collected and evaluated by regulatory bodies.

Overdose and Emergency Response

Overdose and When to Seek Help

Sinaf (Sildenafil) is a medicine with a maximum recommended single dose. Taking a higher-than-prescribed dose increases the risk and severity of dose-dependent adverse effects. Since Sinaf is a strong vasodilator, a key risk of overdose is a significant drop in blood pressure (hypotension).

Signs of a potential Sinaf overdose may include intense flushing, severe headache, dizziness or lightheadedness, faintness, sudden vision changes (such as blurred vision or a blue tint to objects), and racing heartbeat (tachycardia).

If you suspect an overdose, immediately contact emergency medical services or a poison control center. Do not wait for symptoms to worsen.

Medical Emergencies Requiring Immediate Action

Seek emergency medical care immediately if you experience any of the following serious symptoms, as these may indicate a severe adverse reaction or a medical emergency:

Symptom Description
Prolonged Erection An erection that is painful or lasts longer than 4 hours (Priapism). This is a medical emergency that can cause permanent damage.
Sudden Vision Loss A sudden decrease or complete loss of vision in one or both eyes.
Chest Pain Chest pain, pressure, or discomfort, especially if accompanied by nausea, sweating, or pain spreading to the jaw or shoulder.
Severe Allergic Reaction Swelling of the face, lips, tongue, or throat; difficulty breathing; or hives.

Therapeutic Uses of Sinaf

Understanding Sinaf: Primary Indications and Clinical Benefits

Sinaf is a medication primarily utilized in the management of erectile dysfunction (ED) in adult men. It belongs to a class of drugs known as phosphodiesterase type 5 (PDE5) inhibitors, which act on specific biochemical pathways to facilitate physiological responses during sexual stimulation.

Main Uses

The principal application of Sinaf is the treatment of erectile dysfunction, a condition characterized by the persistent or recurrent inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.

For the medication to function effectively, sexual stimulation is required. The active component helps to regulate the enzyme responsible for blood flow in the penile tissue, allowing for a natural response to arousal. It is not indicated for use in women or pediatric populations.

Clinical Benefits and Mechanisms

The therapeutic benefits of Sinaf are centered on its ability to restore impaired erectile function. By inhibiting the PDE5 enzyme, the medication supports the following processes:

  • Enhanced Vasodilation: It aids in the relaxation of smooth muscle cells within the blood vessels of the penis.
  • Improved Blood Flow: This relaxation allows for increased blood inflow into the corpus cavernosum, which is essential for an erection.
  • Duration of Action: The pharmacological profile of the medication allows for a specific window of efficacy, providing flexibility for the user within that timeframe.

Impact on Quality of Life

Beyond the physiological effects, the successful management of erectile dysfunction with Sinaf may contribute to improved psychological well-being. By addressing the physical barriers to sexual function, the medication can help reduce the anxiety and stress often associated with ED, potentially improving interpersonal relationships and overall confidence in sexual health.

Eligibility and Restrictions for Use

Official Eligibility Profile for Sinaf

Regulatory documents define specific populations who are ineligible or require restricted use of Sinaf based on safety data and pre-existing medical conditions.

Contraindicated Populations (Must Not Use) Eligibility-Related Restrictions (Use with Caution)
Known hypersensitivity to Sinaf or excipients. Patients with hepatic or renal impairment may require a lower starting dose due to altered clearance.
History of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). Patients concurrently using alpha-blockers need specific medical evaluation due to the risk of symptomatic hypotension.
Certain severe cardiovascular conditions where sexual activity is advised against. Individuals with anatomical deformation of the penis or conditions predisposing to priapism (e.g., sickle cell anemia).
Recent history (e.g., within 6 months) of myocardial infarction or stroke. Patients with bleeding disorders or active peptic ulceration.

Age and Physiological Status: Sinaf is typically indicated for adults. Use in pediatric populations is generally not established or not indicated. For women, the drug is generally not indicated for use, and it is not recommended during pregnancy or lactation.

Note: Eligibility is conditional on the patient not possessing any listed absolute contraindications and requiring specific monitoring or dose adjustment if they fall into a restricted-use group. This structure reflects the formal patient safety and exclusion criteria outlined in government labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes formally documented interaction patterns for Sinaf (Oxymetazoline, Phenylephrine), based strictly on governmental regulatory information.


Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), Ergot Alkaloids, Antihypertensive Agents.
Mechanistic basis of interactions Inhibition of Monoamine Oxidase (MAO); Pharmacodynamic Synergism with other pressor agents.
Timing-based interaction rules Co-administration with other Intranasal Products may slow the absorption rate of the concomitantly administered product.
Interaction-related restrictions Co-administration with MAOIs is officially prohibited or strictly not recommended.

Official Interaction Statements

  • The combination with Monoamine Oxidase Inhibitors is classified as a contraindicated combination due to the documented risk of severe hypertensive crisis.
  • Co-administration with Tricyclic Antidepressants or Ergot Alkaloids may potentiate the vasopressor effects, which carries a defined risk of inducing hypertension.
  • Sinaf's sympathomimetic action may officially reduce the efficacy of Antihypertensive Agents, including Beta-Blockers, a documented interaction pattern.
  • Interaction-related risks are officially heightened for populations with Uncontrolled Hypertension or Active Thyroid Disease.

Connection to the Overall Interaction Profile

The regulatory documentation defines the product’s interaction structure through its alpha-adrenergic agonist effects, leading to a core classification of a Contraindicated Combination with MAOIs. This profile includes documented pharmacodynamic synergism with other pressor substances and an officially recognized potential for efficacy reduction concerning co-administered antihypertensive therapies.

Mechanism of Action

Mechanism of Action: alpha-Adrenergic Agonism

Sinaf's function is initiated by direct receptor agonism at the alpha1- and alpha2-adrenergic receptors located on the vascular smooth muscle within the nasal mucosa. The active ingredients, Phenylephrine and Oxymetazoline, mimic endogenous catecholamines by binding directly to these receptors, thereby engaging the signal transduction pathway.

Activation of the alpha1-adrenergic receptors triggers the Gq protein cascade, resulting in the rapid mobilization of intracellular calcium ions ( Ca^2+). This surge in calcium acts as the molecular stimulus that forces the vascular smooth muscle fibers to contract, causing vasoconstriction of the nasal arterioles and capacitance venules.

The combination of components exhibits functional complementarity: Phenylephrine provides rapid signal initiation, while Oxymetazoline's high affinity and partial alpha2-adrenergic receptor agonism provide a sustained duration of effect. This coordinated vasoconstriction restricts local blood volume, resulting in the detumescence (physiological reduction in volume) of the mucosal tissue, which establishes and maintains reduced mucosal size.

Dosage and Administration Information

Official Administration Protocol for Sinaf

Sinaf is a medication standardized for topical intranasal use only, applied directly into the nasal passages as a solution or spray. The official administration guidelines define the specific route, dose, frequency, and duration of use.

Labeled Dosing and Administration

Instruction Requirement
Route of Administration Intranasal (Topical)
Dosing Schedule 2 or 3 sprays (0.05% concentration) administered into each nostril.
Frequency Must be used no more often than every 10 to 12 hours; usage is capped at two doses in any 24-hour period.
Duration Constraint Short-term use only, limited to a maximum of 3 consecutive days of administration.
Administration Technique The head must be held upright during application, and the user must sniff deeply while administering the spray.

The proper use of the nasal spray is governed by strict timing and course limitations, establishing the administration protocol. The frequency pattern defines Sinaf as an intermittent, as-needed product, rather than a continuous daily treatment, with the 3-day constraint being a core procedural rule.

Population-Specific Rules

For children aged 6 to under 12 years, the same standard dosing schedule of 2 or 3 sprays in each nostril is used; however, this administration must occur with adult supervision. Use in children under 6 years of age requires prior determination by a healthcare provider. Furthermore, the container is restricted to single-person use and should not be shared between individuals.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sinaf

Evidence for Temporary Relief of Nasal Congestion

The research base for this type of medicine includes short-term Randomized Controlled Trials (RCTs). Studies explored the use of this treatment in research exploring nasal stuffiness associated with the common cold and upper respiratory allergies such as hay fever. Research examined both patient-reported outcomes describing perceived discomfort and objective measures of airflow, such as rhinomanometry. Findings describe patterns observed in the studies where an initial measurement change in nasal airflow and in patient-reported stuffiness was observed shortly after administration. Research highlights changes measured during the study period, helping to contextualize how patients reported their experience during acute episodes.

It is important to note that much of the long-standing evidence is derived from studies on oxymetazoline monotherapy (one of the active ingredients), rather than the specific combination of Oxymetazoline and Phenylephrine. Therefore, findings regarding the specific combination product are often considered by regulators to be related to the established data on the single agents.


Duration of Effect and Follow-up Studies

Studies have specifically monitored the time frame over which observed changes in nasal congestion were maintained. Research exploring short-term symptom changes was studied for its duration. These findings indicate that the data show patterns related to an observed effect lasting up to 12 hours after a single dose in some assessments.

The duration of the clinical trials conducted during periods of increased symptom activity is often limited to the expected course of an acute illness. The majority of repeated-dose studies focus on a short period, typically 3 to 10 days, which reflects the context of product use. Follow-up durations were limited, meaning there is less clinical trial data observing outcomes over longer intermediate or long-term periods.


Limitations and Uncertainties in Sinaf Research

Authoritative bodies acknowledge several key limitations in the existing evidence. The comparative evidence is lacking for the specific combination of Oxymetazoline and Phenylephrine; that is, the evidence quality varies across studies, and many high-quality systematic reviews often focus on only one active ingredient. Furthermore, long-term effects are not fully established through controlled trials. Observational research focuses on a phenomenon known as rebound congestion (rhinitis medicamentosa), which was associated with prolonged or excessive use of nasal sprays. Overall, studies help show what has been observed so far, but the evidence highlights what is known — and what is still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Sinaf (FAQ)

Q: What is Sinaf used for?

Sinaf is a prescription medication used to treat erectile dysfunction (ED), also known as impotence, in men. It is also used to treat pulmonary arterial hypertension (PAH), a type of high blood pressure affecting the arteries in the lungs.

Q: How does Sinaf work to treat erectile dysfunction?

Sinaf belongs to a class of medications called phosphodiesterase type 5 (PDE5) inhibitors. For erectile dysfunction, it works by increasing blood flow to the penis when a man is sexually aroused. This helps a man get and maintain an erection.

Q: Is Sinaf safe to take with other medications?

Sinaf can interact with certain other medications, which may cause serious side effects. It is not safe to take Sinaf with:

  • Nitrates (e.g., nitroglycerin), which are often prescribed for chest pain. The combination can cause a sudden, severe drop in blood pressure.
  • Riociguat (a treatment for PAH).
  • Alpha-blockers (used to treat high blood pressure or enlarged prostate) may increase the risk of low blood pressure.

Always tell your doctor about all the medications and supplements you are taking before starting Sinaf.

Q: How should I take Sinaf for erectile dysfunction?

Sinaf is typically taken as a tablet by mouth.

  • For erectile dysfunction, take it about 30 minutes to 4 hours before sexual activity.
  • It should be taken no more than once a day.
  • Do not take more than your prescribed dose.

Your doctor will determine the appropriate dose for you.

Q: What are the common side effects of Sinaf?

Common side effects may include:

  • Headache
  • Flushing (redness and warmth in your face or neck)
  • Upset stomach or indigestion
  • Vision changes (such as a slight blue tint to vision or blurred vision)
  • Dizziness
  • Muscle pain or back pain

If these side effects are persistent or bothersome, talk to your doctor.

Q: What should I do if I miss a dose of Sinaf for pulmonary arterial hypertension (PAH)?

If you are taking Sinaf for pulmonary arterial hypertension (PAH) and miss a dose, take the missed dose as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed dose.

How should Sinaf be stored and disposed of?

Storage and Disposal Requirements for Sinaf

Sinaf must be stored and disposed of according to official regulatory labeling to maintain product stability and ensure public safety.

Storage Conditions

Requirement Instruction
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Do not store above 30 C.
Protection Do not freeze the nasal solution. Keep the product away from excess heat, light, and moisture.
Container Store in the original container and keep the cap tightly closed when not in use.
Child Safety Mandatory: Keep this medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Sinaf must be disposed of using an official drug take-back program. If a take-back option is unavailable, the medicine must be mixed with an undesirable substance (such as dirt or coffee grounds) and placed in a sealed bag before being thrown into the household trash. Sinaf must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sinaf found in:

A-Z Index: